Data are scarce on the head-to-head effi cacy of terlipressin and octreotide as an adjuvant therapy to endoscopic management of variceal bleed. The aim of this study was to compare the effi cacy and safety of terlipressin with octreotide as an adjuvant therapy to endoscopic variceal band ligation in patients with esophageal variceal bleeding.
INTRODUCTION
Gastroesophageal varices are identi ed in about 30 % of patients with compensated cirrhosis and 60 % patients with decompensated cirrhosis (1) . Esophageal variceal bleed (EVB) occurs in 10 -20 % of cirrhotic patients per year and more frequently in those who have large varices (2) . Esophageal variceal bleeding is a medical emergency that carries high mortality despite appropriate management. Endoscopic intervention along with pharmacologic treatment achieves control of bleeding in nearly 70 -80 % of episodes of variceal bleeding (3) .
Endoscopic variceal band ligation (EVL) has been the recommended preferred procedure for the control of acute esophageal variceal bleeding, although endoscopic injection sclerotherapy (EIS) can be used in this setting if EVL proves technically di cult (4) . Adjuvant pharmacological treatment is the standard of care along with EVL for the control of esophageal variceal bleeding.
Terlipressin and octreotide are two common agents used as an adjuvant agent in the management of variceal bleeding. Both agents have been claimed equivalent to endoscopic therapy in randomized studies (5, 6) .
e mechanism of action of octreotide in portal hypertension is not fully understood. Continuous intravenous (IV) octreotide therapy in cirrhotic patients has been proposed as a measure to control hemorrhage from oesophageal varices because of an assumed reduction in portal pressure and splanchnic blood ow (7) . Octreotide had no e ect on hepatic venous pressure gradient or wedged hepatic venous pressure or hepatic blood ow (8) . e safety pro le of octreotide in EVB is good (9) . Terlipressin is a vasopressin analogue and reduces portal hypertension through its splanchnic vasoconstricting activity (10) . Unlike vasopressin, terlipressin is without plasminogen activating activity in patients with variceal bleed and the chances of worsening coronary ischemia are minimal if any (11) .
A randomized controlled trial has compared combination of pharmacologic agent and EVL to EVL alone in patients with acute EVB. In this trial, combination of adjuvant pharmacologic therapy with EVL was superior to EVL alone (12) . A meta-analysis has concluded that combination of pharmacotherapy with endoscopic intervention was more e cacious in achieving initial control of EVB and 5 days hemostasis (13) . However, comparison between terlipressin and octreotide in combination with EVL has not been studied extensively. Large head-to-head clinical trials are not available in the literature in which terlipressin was compared with octreotide as adjunct to EVL for the control of variceal bleed. Hence, we planned an investigator initiated double-blind placebo-controlled clinical trial to compare the e cacy and safety of terlipressin and octreotide in combination with EVL in patients presenting with EVB. Our hypothesis was that e cacy of terlipressin was noninferior to octreotide as an adjuvant therapy for the EVB.
METHODS

Study population
Patients with cirrhosis who presented to the emergency room (ER) of our hospital with upper gastrointestinal (GI) bleed during November 2003 to July 2005 were screened for inclusion a er taking informed written consent from all potential patients or next to kin if the patient was unable to sign the consent.
Exclusion criteria . Patients were excluded from the study if they had nonvariceal bleed on endoscopy or they had gastric variceal / portal hypertensive gastropathy related bleed at endoscopy. Patients were also excluded if they underwent endoscopy a er 24 h because of any reason. Patient who underwent sclerotherapy for EVB were excluded as EIS was used as rescue treatment exclusively when EVL was not possible in this study. Patients with established hepatorenal syndrome or patients with a history of myocardial ischemia (myocardial infarction or unstable angina) in past 6 months or electrocardiographic changes at presentation suggestive of cardiac ischemia (ST segment depression or elevation in contiguous leads) were excluded from the study.
Randomization and blinding . Study subjects were randomized into two groups. Patients, attending physicians, and care providers were blinded to the study medications. Upon receiving information from the investigators through live physician order entry system, the allocation of drug assignment was carried out by pharmacist using computer generated simple random sequence at the central pharmacy of the hospital. e trial medication and placebo were dispensed in look alike preparation so that no one could di erentiate between the placebo and active drug in either arm. e patients were randomized as potential study subjects at initial presentation in the ER, where either study drug had to be started. e nal enrolment in the study was determined at emergency endoscopy ( Figure 1 ).
Group A received terlipressin 2 mg (10 ml) by IV bolus followed by 1 mg (5 ml) IV every 6 h along with a placebo bolus of 100 ml and then infusion by infusion pump at the rate of 50 ml / h for 72 h (0.45 % dextrose saline as placebo for octreotide).
Group B received 100 ml bolus of 100-g IV octreotide prepared as 1 g octreotide in 1 ml of 0.45 % dextrose saline and a placebo 10 ml IV bolus (0.45 % dextrose saline as placebo for terlipressin). e group B then was continued on 50 g / h octreotide as continuous infusion by infusion pump at the rate of 50 ml / h (prepared as 1 g octreotide in 1 ml of 0.45 % dextrose saline) for 72 h and a six hourly IV injection of 5 ml of placebo of terlipressin (0.45 % dextrose saline) equivalent in amount of 1 mg terlipressin for 72 h. e duration of study medicines for 72 h was based upon our earlier observations of using these pharmacologic agents (14) .
Ethical approval .
is double-blind randomized clinical trial was approved by the ethical committee of our university hospital. An informed consent was obtained from all potential
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Patient management
All patients were managed in the GI bleeding control unit, with continuous noninvasive cardiac and hemodynamic monitoring including cardiac rhythm, pulse rate, blood pressure, and oxygen saturation and documented in the patient ' s chart hourly by nurse as per protocol of the bleeding control unit of our hospital. Hemoglobin (Hb) was checked every 6 h for 48 h and then every 12 h till discharge. Likewise, serum creatinine and liver functions were checked every 12 hourly. Packed red blood cells were transfused to maintain Hb up to 10 g / dl. Fresh frozen plasma and platelets were transfused at the discretion of the attending physician. All patients received prophylactic IV antibiotics (ce riaxone 2 g IV daily for 3 days; antibiotics were stopped if there was no other indication to continue). All patients received routine standard supportive management with IV uids, blood sugar monitoring and oral metronidazole or lactulose if indicated.
Endoscopic variceal band ligation was performed in all patients within 24 h of admission, using the Six Shooter Saeed MultiBand Ligator , Wilson-Cook Medical GI Endoscopy . e attending gastroenterologists performed all endoscopies.
Primary end points . Primary end point was e cacy of the agent to control the EVB as de ned in Baveno III consensus statement (14) .
Secondary end points . Length of hospital stay, in-hospital survival, and safety pro le were secondary end points. Excluded after EGD (n =35) (combined EIS and EVBL in 2; EGD >24 h in 3; Gastric varix bleed in 27, portal hypertensive gastropathy bleed in 3)
Final randomization (EGD confirmed EVB) (n =324)
Failed to control EVB (ITT analysis) (n =12)
Control of EVB (ITT analysis) (n =154)
Failed to control EVB (ITT analysis) (n =7) 
Operative defi nitions
Control of variceal bleed . Control of variceal bleed was achieved when any of the following features of Baveno III criteria (of failure to control bleed) were not met. e failure to control bleed was de ned on the basis of Baveno III criteria as (14) : (a) Within 6 h : Either of the following: (i) transfusion of four units blood or more, (ii) inability to achieve an increase in the systolic blood pressure of 20 or to 70 mm Hg or more, and / or (iii) or inability of a pulse reduction to less than 100 per min or a reduction of 20 per min from baseline pulse rate. (b) A er 6 h : Any of the following factors: (i) the occurrence of hematemesis, (ii) reduction of blood pressure of more than 20 mm Hg from 6 h point, and / or (iii) increase of pulse rate of more than 20 per min from the 6 h point on two consecutive readings 1 h apart, (iv) transfusion of 2 units of blood or more (over and above the previous transfusions) required to increase the Hb to above 9 g / dl. (c) Deaths were taken as failure to control bleed in intention to treat analysis.
Hospital stay . Hospital stay was noted in hours and compared. e patients were considered for discharge if bleeding control has been achieved and they had 72 h of adjuvant pharmacologic treatment along with at least 48 h of stay outside bleeding control unit (high dependency unit).
Sample size and statistical analysis
Sample size was based on noninferiority assumptions for the e cacy of two trial drugs. Sample sizes of 157 from the experimental group (terlipressin) and 157 from the standard group (octreotide) would achieve 80 % power at a 5 % signi cance level using a one-sided equivalence test of proportions; so we took the proportion in the standard group (octreotide) as 0.53 and the proportion in the experimental group (terlipressin) being tested for equivalence as 0.50 (resulting from the fact that there is no head-to-head clinical trial of terlipressin and octreotide as an adjuvant therapy) and the maximum allowable di erence between these proportions that still results in equivalence (the range of equivalence) is 0.11. In ating the sample size to 4 % for consent withdrawal or drop outs we needed 163 patients in each arm.
No interim analysis was planned or performed.
Patients were analyzed as per protocol and intention to treat analysis. Frequency distribution was assessed in terms of mean ± 1 s.d. for quantitative variables and number (percentages) for categorical variables. In univariate analysis, the categorical variables were compared in the two groups by using 2 -test or Fisher ' s exact test where appropriate. For continuous variables, the independent sample t -test was used to compare the means in the two treatment arms. Cox regression analysis was carried out for the identi cation of factors likely to be associated with prolonged hospital stay in hours.
All analyses were carried out by using the Statistical Package for Social Sciences (release 13, standard version, SPSS; Chicago, IL, 2004).
RESULTS
Patients ' characteristics
A total of 513 patients presented to ER with upper GI bleed during study period; 371 patients with portal hypertension related bleed were considered for the study. Out of 371 patients, 324 patients ful lled the inclusion criteria and were randomized to two groups; 163 in group A (terlipressin) and 161 in group B (octreotide; Table 1 ). e study population was male dominant with 230 men (71 % ) and women 94 (29 % ). Mean age was 53.2 ± 10.9 years, range 18 -83 years. Both groups were comparable in age, Hb level at presentation in ER, maximum drop in Hb during hospital stay, creatinine, and hemodynamic parameters. When two groups were compared for the base line characteristics, active bleed was seen during upper GI endoscopy at the time of enrolment in 26 (16 % ) and 41 (25.5 % ) patients in groups A and B, respectively ( P = 0.034; Table 1 ).
Chronic hepatitis C was the predominant cause of cirrhosis followed by non-B, non-C, and chronic hepatitis B ( Table 1 ) . Majority of patients belonged to Child -Pugh classes B and C. Patients with advanced Child -Pugh scores that is classes B and C were present uniformly in both groups ( Table 1 ).
Management and outcome of variceal bleeding
e control of variceal bleed was achieved in 318 out of 324 subjects; 158 of 163 (96.9 % ) patients in group A and 160 patient out of 161 patient (99.4 % ) in group B ( P = 0.107, Fisher ' s exact test). Out of these six patients in whom we failed to control the variceal bleed, three died. Overall sixteen patients died in the trial; nine in group A and seven in group B ( P = 0.313).
In the intension to treat analysis, " control of variceal bleed " was noted in 305 patients (94.13 % ); 151 patients (92.63 % ) in group A and 154 (95.6 % ) patients in group B (con dence interval (CI): 0.219 -1.492). is CI was falling into our a priory range of equivalence of 11 % (noninferiority region). Table 2 shows the features in the two groups in whom control of variceal bleed was achieved on the basis of intension to treat analysis. Requirement of packed cell transfusions to maintain Hb up to 10 g / dl were 3.7 ± 2.3 units in the terlipressin group and 3.9 ± 2.5 units in octreotide group ( P = 0.273). Requirement of platelets and fresh frozen plasma transfusions were found similar in both groups.
Factors associated with prolonged hospital stay
Length of hospital stay in groups A and B was 108.40 ± 34.81 and 126.39 ± 47.45 h, respectively ( P ≤ 0.001). On Cox regression analysis, high pulse, low Hb, prothrombin time, blood in nasogastric aspirate and portosystemic encephalopathy (PSE) were predictors of prolonged hospital stay ( Table 3 ) .
We did not encounter cardiovascular side e ects in either arm of the study. None of the patients developed chest pain or ST segment changes during hospital stay.
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e results of our study have shown that terlipressin was noninferior to octreotide in its e cacy to control variceal bleed when used as adjuvant agent in combination with endoscopic band ligation in patients with EVB. e overall e cacy of combination of either terlipressin or octreotide with endoscopic band ligation in EVB was 94.13 % . A relatively small randomized trial of 30 patients from Italy showed that terlipressin was superior to octreotide when pharmacotherapy was used alone in acute EVB (17) . Although another study had shown that both octreotide and terlipressin agents were equally e cacious in the control of EVB (18) . A Cochrane systemic review had recommended the use of terlipressin as the rst line of treatment in control of EVB as terlipressin was found to reduce the relative mortality risk by 34 % (19) . We found no di erence in mortality among the groups. Unfortunately 1 month mortality a er the index bleed was not assessed because many patients came from remote areas and it was impossible to follow them.
is study has also demonstrated another important feature that the use terlipressin was associated with shorter hospital stay. is could be resulting from the fact that higher number DISCUSSION is is the largest randomized comparison of e cacy and safety of terlipressin and octreotide in the management of EVB as adjuvant to endoscopic intervention in EVB. is cohort of patients with EVB was dominated by male gender, and majority of the patients had advanced liver disease; Child ' s -Pugh classes B and C being present in 40 % and 54 % , respectively. Predominance of advanced chronic liver disease was concordant with other therapeutic trials of EVB, in which patients with Child ' s -Pugh classes B and C were 43 % and 39 % , respectively (13) . Hepatitis C related cirrhosis was the most common etiology of liver disease in this series that re ects the higher prevalence of hepatitis C virus in the region (15) .
Esophageal variceal band ligation (EVL) had replaced injection sclerotherapy (EIS) for EVB as EVL was superior to EIS (16) . We included patients who underwent EVL for EVB only; as EVL was rst line intervention practiced at our center and would do sclerotherapy as a rescue whenever EVL was technically di cult. Hence patients were excluded if they had sclerotherapy alone or in combination with EVL to have uniformity. Includes patients with alcohol liver disease and coinfection with HBV/HDV and HBV/HCV. * P value = 0.034. of patients in terlipressin had signi cantly low rate of active bleeding compared to patients in octreotide group at base line when seen at initial endoscopic intervention and also PSE was seen in lower proportion of patients in the terlipressin group. In the Cox regression analysis, high pulse, low Hb, prothrombin time, blood in nasogastric aspirate, and PSE were predictors of prolonged hospital stay. However, to the best of our knowledge no previous study had demonstrated the e ect of terlipressin and octreotide on the duration of hospital stay and hence further studies are required to clarify this issue. Although the cost analysis was not the objective of the current study, however, the calculated cost of 3 days of terlipressin was US $180 whereas that of octreotide was US$ 280 at our institution. Considering the cost di erence between octreotide and terlipressin and the di erence in the duration of hospital stay it would be appropriate to study the relative cost e ectiveness of terlipressin and octreotide as adjuvant to EVL in the management of EVB. e safety of terlipressin had been questioned time and again as this may lead to or worsen the ongoing coronary ischemia.
e Cochrane review conducted few years ago evaluated the safety of terlipressin in terms of adverse e ects, drug withdrawal, and deaths, found no di erence in terms of control of bleeding or rebleeding rate in terlipressin or octreotide (19) . ough we did not encountered adverse cardiovascular events in any group, however, the safety of terlipressin cannot be generalized by this study as patients with active ischemia or recent myocardial infarction were excluded because of ethical reasons.
In our study, we took a priori range of equivalence (noninferiority region) as 11 % . e CI of our primary outcome measure was well with in this range and hence terlipressin was noninferior to octreotide. In the sample size calculation, the proportion in the octreotide was taken as 53 % and for terlipressin we took 50 % as there was no trial available as an adjuvant therapy. is was carried out to capture the maximum sample size. In this trial, the control of variceal bleeding was much higher than expected as 94.13 % . is may be because of the fact that the patients who were not t for the endoscopy in the initial 24 h were excluded. Patients were also excluded who underwent sclerotherapy for EVB as EIS was used as rescue treatment.
In our study, the patients were randomized as potential study subjects at initial presentation to the ER, as either study drug had to be started from the presentation. e nal eligibility to be enrolled in the study was decided once esophagogastroduodenoscopy was performed within initial 24 h and con rmed EBV as their source of bleeding. Ideally, randomization should be carried out once nal inclusion and exclusion criteria are met. In our study, we opted to start the trial medication before nal inclusion to utilize the vasoactive e ect of terlipressin and octreotide to control variceal bleed and hence give the better endoscopic view to perform therapeutic intervention, is was the limitation in the design of our study. e e cacy of terlipressin was noninferior to octreotide as an adjuvant therapy for the control of EVB and in-hospital survival. e length of hospital stay in terlipressin group was signi cantly shorter without any clinical importance. e predictors of prolonged hospital stay were low Hb, high pulse, prolonged prothrombin time, blood at nasogastric aspirate, and PSE.
No noticeable side e ects were observed in either group speci cally the cardiovascular side e ects. Studies are required for further evaluation of di erence in the duration of hospital stay and cost e ective comparison between terlipressin and octreotide in patients with EVB.
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